Drugs / RNA-LPs
RNA-LPs
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07492316 | Apr 2026 → Sep 2030 expected | medulloblastoma | University of Florida | Recruiting | No outcome recorded |
| Phase 1 | NCT06389591 | Dec 2024 → Dec 2026 expected | glioblastoma | University of Florida | Recruiting | No outcome recorded |
| Phase 1 | NCT04573140 | Dec 2021 → Jul 2027 expected | adult glioblastoma | University of Florida | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNA-LPs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07492316 ↗ |
| Known as | DP2 | “RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)” NCT06389591 ↗ |
| Known as | Drug Product 2 | “RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)” NCT06389591 ↗ |
| Known as | RNA loaded lipid particles | “Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded...” NCT04573140 ↗2“RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)” NCT06389591 ↗ “RNA loaded lipid particles, RNA-LPs” NCT07492316 ↗ |
| Modality | Vaccine | “RNA-LP vaccines will be administered intravenous.” NCT04573140 ↗ |
| Route | Intravenous | “RNA-LP vaccines will be administered intravenous.” NCT04573140 ↗ |